Announced on its homepage: “Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases NEW YO…”.
Observed on the company’s website; business claims are not independently verified.
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
August 2025 – September 2026 · 3 captures · latest observed messagingAccro Bioscience(Suzhou)Limited